Copyright
©The Author(s) 2015.
World J Gastroenterol. Aug 28, 2015; 21(32): 9526-9533
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9526
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9526
Ref. | No. of patients | Patient characteristics | Antiviral Scheme, (duration) | On treatment virological response (%) | SVR (%) |
Pungpapong et al[28] | 55 | Fibrosis 3-4: 29%, Decompensated cirrhosis: 4%, Cholestatic recurrence: 15% | SOF + SMV ± RBV(12 wk) | 98 (EOT) | 91 |
Brown et al[29] | 143 | Cirrhosis: 60%, MELD score > 10: 14%Previous DAA failure: 9% | SOF + SMV ± RBV (12-24 wk) | - | 90 |
Satokar et al[30] | 59 | Fibrosis F3/F4: 51%,Treatment experience: 71% | SOF + SMVSOF + SMV + RBVSOF + RBV | 62 50 43 (4 wk) | - |
Gordon et al[31] | 17 | Fibrosis: range: 0-4 | SOF + SMV(12 wk) | 100 (EOT) | - |
Gutierrez et al[32] | 32 | - | SOF + SMV ± RBV(12 wk) | 93 (EOT) | - |
Punzalan et al[37] | 10 | Median Fibrosis: 2.5,Treatment experience: 40% | SOF + SMV ± RBV(12 wk) | 100 (EOT) | 100 |
Lutchman et al[33] | 41 | Treatment experience: 56% | SOF + SMV orSOF + RBV(12-24 wk) | 100 (8 wk) | - |
Nair et al[34] | 22 | All patients with fibrosis ≥ 3 or decompensated cirrhosis | SOF + SMV ± RBV(12 wk) | 100 (EOT) | - |
Ripper et al[35] | 25 | Treatment experience: 64% | SOF + SMV ± RBV(12 wk) | 100 (8 wk) | 75 |
O'Dell et al[38] | 16 | - | SOF + SMV ± RBV | 100 EOT | 100 |
Alsabbagh et al[36] | 17 | Fibrosis F3-4: 40%, Treatment experience: 41% | SOF + SMV (n = 11)SOF + RBV (n = 6)(24 wk) | 100 (4 wk) | - |
- Citation: Cholongitas E, Pipili C, Papatheodoridis G. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. World J Gastroenterol 2015; 21(32): 9526-9533
- URL: https://www.wjgnet.com/1007-9327/full/v21/i32/9526.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i32.9526